Desloratadine and loratadine stand out among common H<sub>1</sub>-antihistamines for association with improved breast cancer survival
Ildikó Fritz, Philippe Wagner, Per Broberg, Rickard Einefors, Håkan Olsson
Abstract
BACKGROUND: -antihistamines and breast cancer mortality. MATERIAL AND METHODS: -antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women diagnosed with breast cancer 2006-2013. Both peri- and post-diagnostic antihistamine use was analyzed using Cox regression models. Analyses were stratified for age and subgroup analyses based on estrogen receptor status and menopausal status were performed. RESULTS: = .012), relative to nonusers, regardless of patient age, menopause, estrogen receptor status or stage of the tumor, or whether breast cancer-specific or overall survival was analyzed. The survival of users of other antihistamines varied relative to non-users. CONCLUSION: -antihistamine use and survival in other malignancies.